Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18,334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Takahashi S, Oridate N, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, Yokota T, Yamazaki T, Takahashi M, Ueda T, Hanai N, Yamaguchi H, Hara H, Yoshizaki T, Yasumatsu R, Nakayama M, Shiga K, Fujii T, Mitsugi K, Takahashi K, Nohata N, Gumuscu B, Swaby RF, Tahara M. Takahashi S, et al. Among authors: tanaka k. Int J Clin Oncol. 2022 Dec;27(12):1805-1817. doi: 10.1007/s10147-022-02233-6. Epub 2022 Oct 20. Int J Clin Oncol. 2022. PMID: 36264378 Free PMC article. Clinical Trial.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Immunotherapy for squamous cell carcinoma of the head and neck.
Yokota T, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Okano S, Imamura Y, Ariizumi Y, Hayashi R; Japan Clinical Oncology Group (JCOG) Head and Neck Cancer Study Group. Yokota T, et al. Among authors: tanaka k. Jpn J Clin Oncol. 2020 Sep 28;50(10):1089-1096. doi: 10.1093/jjco/hyaa139. Jpn J Clin Oncol. 2020. PMID: 32776100 Review.
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
Okano S, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Yokota T, Imamura Y, Ariizumi Y, Akimoto T, Hayashi R. Okano S, et al. Among authors: tanaka k. Jpn J Clin Oncol. 2021 Feb 8;51(2):173-179. doi: 10.1093/jjco/hyaa220. Jpn J Clin Oncol. 2021. PMID: 33290543 Review.
Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial.
Imamura Y, Tanaka K, Kiyota N, Hayashi H, Ota I, Arai A, Iwae S, Minami S, Yane K, Yamazaki T, Nagatani Y, Toyoda M, Takahama T, Sakai K, Nishio K, Otsuki N, Nibu KI, Minami H. Imamura Y, et al. Among authors: tanaka k. Med Oncol. 2021 Sep 22;38(11):128. doi: 10.1007/s12032-021-01581-z. Med Oncol. 2021. PMID: 34550483 Clinical Trial.
Systemic therapy for salivary gland malignancy: current status and future perspectives.
Imamura Y, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ota I, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Yokota T, Okano S, Tanaka K, Onoe T, Ariizumi Y, Homma A. Imamura Y, et al. Among authors: tanaka k. Jpn J Clin Oncol. 2022 Apr 6;52(4):293-302. doi: 10.1093/jjco/hyac008. Jpn J Clin Oncol. 2022. PMID: 35134985 Review.
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, Mitani H, Iwae S, Fujimoto Y, Onozawa Y, Hanai N, Ogawa T, Hara H, Monden N, Shimura E, Minami S, Fujii T, Tanaka K, Homma A, Yoshimoto S, Oridate N, Omori K, Ueda T, Okami K, Ota I, Shiga K, Sugasawa M, Asakage T, Saito Y, Murono S, Nishimura Y, Nakamura K, Hayashi R; Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG). Kiyota N, et al. Among authors: tanaka k. J Clin Oncol. 2022 Jun 20;40(18):1980-1990. doi: 10.1200/JCO.21.01293. Epub 2022 Mar 1. J Clin Oncol. 2022. PMID: 35230884 Free PMC article. Clinical Trial.
Human papillomavirus-related oropharyngeal carcinoma.
Saito Y, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ota I, Yokota T, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Okano S, Imamura Y, Ariizumi Y, Hayashi R. Saito Y, et al. Among authors: tanaka k. Jpn J Clin Oncol. 2022 Jul 8;52(7):700-706. doi: 10.1093/jjco/hyac049. Jpn J Clin Oncol. 2022. PMID: 35383359 Review.
18,334 results
You have reached the last available page of results. Please see the User Guide for more information.